INOInovio Pharmaceuticals Inc
INO
Inovio Pharmaceuticals Inc92,253
Mkt Cap
$114.69MVolume
924,613.0052W High
$2.9852W Low
$1.30PE Ratio
-0.64INO Fundamentals
Price
$1.66Prev Close
$1.68Open
$1.7250D MA
$1.65Beta
1.23Avg. Volume
1.03MEPS (Annual)
-$1.81P/B
-11.52Rev/Employee
$583.42$32.44
Poll
Earnings Recap
• Reported GAAP EPS of $0.31 up 151.67% YoY • Inovio projects its cash, cash equivalents, and short-term investments will support operations into the fourth quarter of 2026, with an estimated operational net cash burn of approximately $22M for the first quarter of 2026.
Bullish
Inovio's BLA for INO-3107 was accepted for FDA review, and the company advanced next-generation DNA medicine technology with published trial results. Inovio also initiated a new clinical collaboration while reducing R&D expenses.
Bearish
Inovio faces regulatory uncertainty for INO-3107's accelerated approval pathway and a significant decrease in cash to $58.5 million. The company's fourth-quarter net income was largely due to a volatile non-cash gain.